Evidence map›Paper›PMID 28978973›Full record

ArticleThe American journal of gastroenterology2017

Editorial: Statins and Liver Disease: Is it Time to Recommend Statins to Prevent Liver Disease Progression?

Jennifer C Price, Phyllis C Tien

Open access · greenAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Pleotropic effects of statins: the dilemma of wider utilization of statin.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023
    Review
  3. Potential hepatoprotective effects ofFrontiers in pharmacology · 2022
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jennifer C PriceDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Phyllis C TienDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
University of California, San Francisco · US

Funding

HIV, HCV, and gender effects on Liver, Bone, and Vascular HealthK24AI108516 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TIEN, PHYLLIS C · 2013 to 2024
$1.5M
NIAID NIH HHS K24 AI108516
6 · The paper itself

Abstract

Evidence is emerging that statins may reduce liver-related adverse outcomes in individuals with chronic liver disease. In this issue of the American Journal of Gastroenterology, Kamal et al. found in their meta-analysis that statin use was associated with a reduced risk of fibrosis progression, decompensated cirrhosis, and mortality. These encouraging findings suggest beneficial liver effects of statins. However, the overall quality of the evidence is low because 9 of the 10 studies included in the meta-analysis were observational. More robust studies, including randomized trials and research on safety in patients with advanced liver disease, are needed before statins can be routinely recommended for prevention of liver-related morbidity and mortality.

Indexed as

Chronic DiseaseDisease ProgressionHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLiver DiseasesSurvival AnalysisTreatment OutcomeHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID28978973
PMCPMC8842818
OpenAlexW2763896419

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.